Daniel Canelas | Universidade de Coimbra (original) (raw)

Papers by Daniel Canelas

Research paper thumbnail of Can ePROMs improve the understanding and management of lung cancer patients’ Quality of Life? A Scoping review (Preprint)

Journal of Medical Internet Research, Feb 4, 2023

Background: Electronic patient-reported outcome measures (ePROMs) are essential to clinical pract... more Background: Electronic patient-reported outcome measures (ePROMs) are essential to clinical practice and research. The growth of eHealth technologies has provided unprecedented opportunities to collect information systematically through ePROMs. Although they are widely used in scientific research, more evidence is needed to determine their use and implementation in daily clinical practice. For example, when diagnosed, patients with lung cancer are at an advanced stage of the disease. This entails tremendous burden because of high mortality and losses in the different dimensions of the human being. In this case, monitoring symptoms and other outcomes help improve the patient's quality of life. Objective: ePROMs offered unprecedented opportunities to collect information systematically. Our goal was to demonstrate that ePROMs are more useful in controlling patient symptoms, lung cancer, and overall survival than their alternatives, such as nonelectronic PROMs. Methods: This exploratory review considered articles published between 2017 and 2022 identified through searches of PubMed, Scopus, Cochrane, CINAHL, and PsycINFO. We found 5097 articles; after removing the duplicates, we reduced them to 3315. After reading the summary, we were left with 56. Finally, after applying the exclusion criteria, we reviewed 12. The 5-step framework by Arksey and O'Malley was used to refine the initial search results with the following research questions: Do ePROMs help physician-patient communication? To what extent do they improve decision-making? Are institutions and their digitization policies barriers to or facilitators of this process? and What else is needed for routine implementation? Results: This review included 12 articles. We found that ePROMs are an integrative and facilitative communication tool, highlighting their importance in the relationship between palliative care and medical oncology. ePROMs help assess patient symptoms and functionality more accurately and facilitate clinical decision-making. In addition, it allows for more precise predictions of overall patient survival and the adverse effects of their treatments. The main institutional obstacles are the initial

Research paper thumbnail of Improving the Understanding and Managing of the Quality of Life of Patients With Lung Cancer With Electronic Patient-Reported Outcome Measures: Scoping Review (Preprint)

BACKGROUND Electronic patient-reported outcome measures (ePROMs) are essential to clinical practi... more BACKGROUND Electronic patient-reported outcome measures (ePROMs) are essential to clinical practice and research. The growth of eHealth technologies has provided unprecedented opportunities to collect information systematically through ePROMs. Although they are widely used in scientific research, more evidence is needed to determine their use and implementation in daily clinical practice. For example, when diagnosed, patients with lung cancer are at an advanced stage of the disease. This entails tremendous burden because of high mortality and losses in the different dimensions of the human being. In this case, monitoring symptoms and other outcomes help improve the patient’s quality of life. OBJECTIVE ePROMs offered unprecedented opportunities to collect information systematically. Our goal was to demonstrate that ePROMs are more useful in controlling patient symptoms, lung cancer, and overall survival than their alternatives, such as nonelectronic PROMs. METHODS This exploratory re...

Research paper thumbnail of Can ePROMs improve the understanding and management of lung cancer patients’ symptoms? A Scoping review (Preprint)

Research paper thumbnail of O paradoxo da obesidade e as suas implicações clínicas

Research paper thumbnail of Doença Celíaca, Gastrite Atrófica Autoimune e Helicobacter pylori na Anemia Refratária ao Ferro Oral

Revista Portuguesa de Clínica Geral

CELIAC DISEASE, AUTOIMMUNE ATROPHIC GASTRITIS AND HELICOBACTER PYLORI IN ORAL IRON THERAPY RESIST... more CELIAC DISEASE, AUTOIMMUNE ATROPHIC GASTRITIS AND HELICOBACTER PYLORI IN ORAL IRON THERAPY RESISTANCE ANEMIA Objectives: Identify the number of celiac disease (CD), autoimmune atrophic gastritis (AAG) and the Helicobacter pylori (Hp) infection in patients with iron-refractory iron deficiency anemia (RIA). Type of study: Observational, retrospective, longitudinal. Location: Hospital center hematology unit in the north region of Portugal. Population: All first hematology consultations of patients with RIA between 2011 and 2016. Methods: Collection of data using the electronic clinical file (socio-demographic, origin of the consultation request and diagnostic tests data). Microsoft Excel 2016® was used to analyze and process the data. Results: We identified 48 cases of iron-refractory iron deficiency anemia (9.3% of 518 patients with iron deficiency anemia). A complete screening for CD, AAG and the infection by Hp was made for 24 patients. A partial screening (only for one or two of these diseases) was made for 19 patients. In the 43 cases that at least one of the screenings were made, the prevalence of CD was about 4.7%, the prevalence of AAG was 14% and the infection by Hp was 30.2%. We couldn't evaluate the Hp eradication because it wasn't confirmed in six of 13 cases identified with this pathology. In the other seven cases, Hp eradication solved anemia in only one patient. Conclusion: We identified a high percentage of patients with iron-refractory iron deficiency anemia that suffer from AAG and infection by Hp, as is referred to in international studies. These findings reinforce the role of these diseases in iron-refractory iron deficiency anemia in the Portuguese population. This work reinforces the need to screen for CD, AAG and Hp infection in iron-refractory iron deficiency anemia.

Research paper thumbnail of Can ePROMs improve the understanding and management of lung cancer patients’ Quality of Life? A Scoping review (Preprint)

Journal of Medical Internet Research, Feb 4, 2023

Background: Electronic patient-reported outcome measures (ePROMs) are essential to clinical pract... more Background: Electronic patient-reported outcome measures (ePROMs) are essential to clinical practice and research. The growth of eHealth technologies has provided unprecedented opportunities to collect information systematically through ePROMs. Although they are widely used in scientific research, more evidence is needed to determine their use and implementation in daily clinical practice. For example, when diagnosed, patients with lung cancer are at an advanced stage of the disease. This entails tremendous burden because of high mortality and losses in the different dimensions of the human being. In this case, monitoring symptoms and other outcomes help improve the patient's quality of life. Objective: ePROMs offered unprecedented opportunities to collect information systematically. Our goal was to demonstrate that ePROMs are more useful in controlling patient symptoms, lung cancer, and overall survival than their alternatives, such as nonelectronic PROMs. Methods: This exploratory review considered articles published between 2017 and 2022 identified through searches of PubMed, Scopus, Cochrane, CINAHL, and PsycINFO. We found 5097 articles; after removing the duplicates, we reduced them to 3315. After reading the summary, we were left with 56. Finally, after applying the exclusion criteria, we reviewed 12. The 5-step framework by Arksey and O'Malley was used to refine the initial search results with the following research questions: Do ePROMs help physician-patient communication? To what extent do they improve decision-making? Are institutions and their digitization policies barriers to or facilitators of this process? and What else is needed for routine implementation? Results: This review included 12 articles. We found that ePROMs are an integrative and facilitative communication tool, highlighting their importance in the relationship between palliative care and medical oncology. ePROMs help assess patient symptoms and functionality more accurately and facilitate clinical decision-making. In addition, it allows for more precise predictions of overall patient survival and the adverse effects of their treatments. The main institutional obstacles are the initial

Research paper thumbnail of Improving the Understanding and Managing of the Quality of Life of Patients With Lung Cancer With Electronic Patient-Reported Outcome Measures: Scoping Review (Preprint)

BACKGROUND Electronic patient-reported outcome measures (ePROMs) are essential to clinical practi... more BACKGROUND Electronic patient-reported outcome measures (ePROMs) are essential to clinical practice and research. The growth of eHealth technologies has provided unprecedented opportunities to collect information systematically through ePROMs. Although they are widely used in scientific research, more evidence is needed to determine their use and implementation in daily clinical practice. For example, when diagnosed, patients with lung cancer are at an advanced stage of the disease. This entails tremendous burden because of high mortality and losses in the different dimensions of the human being. In this case, monitoring symptoms and other outcomes help improve the patient’s quality of life. OBJECTIVE ePROMs offered unprecedented opportunities to collect information systematically. Our goal was to demonstrate that ePROMs are more useful in controlling patient symptoms, lung cancer, and overall survival than their alternatives, such as nonelectronic PROMs. METHODS This exploratory re...

Research paper thumbnail of Can ePROMs improve the understanding and management of lung cancer patients’ symptoms? A Scoping review (Preprint)

Research paper thumbnail of O paradoxo da obesidade e as suas implicações clínicas

Research paper thumbnail of Doença Celíaca, Gastrite Atrófica Autoimune e Helicobacter pylori na Anemia Refratária ao Ferro Oral

Revista Portuguesa de Clínica Geral

CELIAC DISEASE, AUTOIMMUNE ATROPHIC GASTRITIS AND HELICOBACTER PYLORI IN ORAL IRON THERAPY RESIST... more CELIAC DISEASE, AUTOIMMUNE ATROPHIC GASTRITIS AND HELICOBACTER PYLORI IN ORAL IRON THERAPY RESISTANCE ANEMIA Objectives: Identify the number of celiac disease (CD), autoimmune atrophic gastritis (AAG) and the Helicobacter pylori (Hp) infection in patients with iron-refractory iron deficiency anemia (RIA). Type of study: Observational, retrospective, longitudinal. Location: Hospital center hematology unit in the north region of Portugal. Population: All first hematology consultations of patients with RIA between 2011 and 2016. Methods: Collection of data using the electronic clinical file (socio-demographic, origin of the consultation request and diagnostic tests data). Microsoft Excel 2016® was used to analyze and process the data. Results: We identified 48 cases of iron-refractory iron deficiency anemia (9.3% of 518 patients with iron deficiency anemia). A complete screening for CD, AAG and the infection by Hp was made for 24 patients. A partial screening (only for one or two of these diseases) was made for 19 patients. In the 43 cases that at least one of the screenings were made, the prevalence of CD was about 4.7%, the prevalence of AAG was 14% and the infection by Hp was 30.2%. We couldn't evaluate the Hp eradication because it wasn't confirmed in six of 13 cases identified with this pathology. In the other seven cases, Hp eradication solved anemia in only one patient. Conclusion: We identified a high percentage of patients with iron-refractory iron deficiency anemia that suffer from AAG and infection by Hp, as is referred to in international studies. These findings reinforce the role of these diseases in iron-refractory iron deficiency anemia in the Portuguese population. This work reinforces the need to screen for CD, AAG and Hp infection in iron-refractory iron deficiency anemia.